Photoprotection according to skin phototype and dermatoses: Practical recommendations from an expert panel

Interferon alpha for the adjuvant treatment of melanoma: review of international literature and practical recommendations from an expert panel on the use of interferon

Journal of Chemotherapy ◽

10.1179/1973947813y.0000000154 ◽

2013 ◽

Vol 26 (4) ◽

pp. 193-201 ◽

Cited By ~ 11

Author(s):

A. Paolo ◽

Vanna Chiarion-Sileni ◽

Antonio Muggiano ◽

Mario Mandalà ◽

Nicola Pimpinelli ◽

...

Keyword(s):

Interferon Alpha ◽

Adjuvant Treatment ◽

Expert Panel ◽

International Literature ◽

Practical Recommendations

Download Full-text

Erratum to: Management of HCV infection in the penitentiary setting in the direct-acting antivirals era: practical recommendations from an expert panel

Infection ◽

10.1007/s15010-017-0983-6 ◽

2017 ◽

Vol 45 (2) ◽

pp. 249-249

Author(s):

Roberto Ranieri ◽

◽

Giulio Starnini ◽

Sergio Carbonara ◽

Emanuele Pontali ◽

...

Keyword(s):

Expert Panel ◽

Hcv Infection ◽

Direct Acting Antivirals ◽

Direct Acting ◽

Practical Recommendations

Download Full-text

Practical recommendations for the safe use of gadolinium in magnetic resonance imaging: a Delphi expert panel study

Radiologia Brasileira ◽

10.1590/0100-3984.2019.0074 ◽

2020 ◽

Vol 53 (4) ◽

pp. 216-222

Author(s):

Ronaldo Hueb Baroni ◽

Tufik Bauab Jr. ◽

Leonardo Kayat Bittencourt ◽

Giuseppe D’Ippolito ◽

Suzan Menasce Goldman ◽

...

Keyword(s):

Adverse Reactions ◽

Expert Panel ◽

Panel Study ◽

Delphi Panel ◽

Gadolinium Deposition ◽

Published Evidence ◽

Potential Risks ◽

The Brain ◽

Practical Recommendations

Abstract Objective: To assess the practical aspects of the use of various gadolinium-based contrast agents (GBCAs) by radiologists. Materials and Methods: Ten experienced radiologists from different regions of Brazil participated in a Delphi panel querying their use of various GBCAs, including linear and macrocyclic classes (1.0 and 0.5 M), in terms of the choice of agent, volume and dosage of the agents, and associated safety concerns. Results: The response rate was 100% for all questions. GBCAs are safe in terms of acute adverse reactions, and nephrogenic systemic fibrosis is rare. The deposition of gadolinium in the brain and other tissues is a concern among the experts. Macrocyclic agents are preferable to linear agents; an injection volume below 0.1 mL/kg of a 1.0 M agent could result in good-quality images with additional long-term safety, but there is no published evidence to support this recommendation. The majority of experts preferred not to administer GBCAs to pregnant patients. Conclusion: When choosing a GBCA, it is important to consider the characteristics of the gadolinium deposition in patient tissues and minimize potential risks. Furthermore, medical education programs are needed to increase the awareness of the potential risks of gadolinium deposition and thus avoid instances of overexposure to the contrast agent.

Download Full-text

Management of HCV infection in the penitentiary setting in the direct-acting antivirals era: practical recommendations from an expert panel

Infection ◽

10.1007/s15010-016-0973-0 ◽

2016 ◽

Vol 45 (2) ◽

pp. 131-138 ◽

Cited By ~ 7

Author(s):

Roberto Ranieri ◽

◽

Giulio Starnini ◽

Sergio Carbonara ◽

Emanuele Pontali ◽

...

Keyword(s):

Expert Panel ◽

Hcv Infection ◽

Direct Acting Antivirals ◽

Direct Acting ◽

Practical Recommendations

Download Full-text

Expert Panel Discussion among Psoriasis and Psychodermatology Specialists: How Best to Manage Depressed Psoriasis Patients with Brodalumab

SKIN The Journal of Cutaneous Medicine ◽

10.25251/skin.3.6.1 ◽

2019 ◽

Vol 3 (6) ◽

pp. 368-373

Author(s):

Quinn Thibodeaux ◽

Rick Fried ◽

Gary Goldenberg ◽

George Han ◽

Sylvia Hsu ◽

...

Keyword(s):

Consensus Statement ◽

Expert Panel ◽

Work Group ◽

Panel Discussion ◽

Clinical Psychologist ◽

Comfort Zone ◽

Comorbid Depression ◽

The Subject ◽

Practical Recommendations ◽

Treat Patient

Psoriasis patients with comorbid depression represent a common therapeutic challenge for dermatologists. Depressed patients often require the practicing dermatologist to go outside of their comfort zone, and the FDA’s labeling of medications such as brodalumab have further complicated an already difficult-to-treat patient population. A multi-disciplinary work-group consisting of a board-certified psychiatrist, a licensed clinical psychologist, and multiple dermatologists was convened to formulate practical recommendations for the evaluation and treatment of this at-risk population. How to broach the subject of depression and when to refer patients for formal evaluation were discussed. The expert panel also produced a consensus statement regarding the use of brodalumab in patients with both psoriasis and depression.

Download Full-text